Search Results

Your search for Seema A. Bhat, MD, and Jennifer A. Woyach, MD,Seema A. Bhat, MD, and Jennifer A. Woyach, MD matches 2 pages

Showing 1 - 2

By Seema A. Bhat, MD, and Jennifer A. Woyach, MD / November 25, 2020 - Supplement: Hematologic Oncology Almanac

Final ASCEND Results Confirm Acalabrutinib as a Standard for Relapsed CLL

The Bruton’s tyrosine kinase (BTK) inhibitors have been one of the most exciting advances in the treatment of patients with chronic lymphocytic leukemia (CLL) and have led to the development of chemotherapy-free treatments for both treatment-naive as well as relapsed or refractory CLL based on...

leukemia

lymphoma

By Seema A. Bhat, MD, and Jennifer A. Woyach, MD / August 25, 2020

Final ASCEND Results Confirm Acalabrutinib as a Standard for Relapsed CLL

The Bruton’s tyrosine kinase (BTK) inhibitors have been one of the most exciting advances in the tre atment of chronic lymphocytic leukemia (CLL) and have led to the development of chemotherapy-free treatments for both treatment-naive as well as relapsed or refractory CLL based on studies where...

Nov

Today In Oncology

Search Results

Your search for Seema A. Bhat, MD, and Jennifer A. Woyach, MD,Seema A. Bhat, MD, and Jennifer A. Woyach, MD matches 2 pages

Final ASCEND Results Confirm Acalabrutinib as a Standard for Relapsed CLL

Final ASCEND Results Confirm Acalabrutinib as a Standard for Relapsed CLL

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

International Cancer Organizations Present Collaborative Work During Oncology Event in China

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Suicide-Related Mortality in Male AYA Cancer Survivors

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC